MK
1
Inpharma 1515 - 26 Nov 2005 ■ An experimental integrase inhibitor, MK 0518, * effectively reduces viral RNA in previously untreated patients with HIV infection, according to initial findings from a study presented at the European AIDS Clinical Society meeting. In this multicentre, phase II trial, 35 antiretroviral-naive patients with HIV infection were randomised to receive MK 0518 at a dose of 100mg, 200mg, 400mg or 600mg, or placebo, twice daily for 10 days. HIV RNA reductions of 1.7 to 2.2 log10 copies/mL were observed across the MK 0518 groups, compared with a reduction of only 0.2 log10 copies/mL for the placebo recipients (p < 0.001). More than 50% of each MK 0518 group achieved HIV RNA levels of < 400 copies/mL by day 10. The treatment was also well tolerated with no discontinuations due to adverse effects or serious adverse effects reported. * Merck & Co; phase II for HIV-1 infection in Ireland Merck and Co Inc. Results of an Initial Phase II Study Showed That MK-0518, an Investigational Integrase Inhibitor, Provided Superior Reduction in HIV Viral RNA vs. Placebo in Treatment-Naive HIV-infected Patients. Media Release : 18 Nov 2005. Available from: URL: http:// www.merck.com 809057198 1 Inpharma 26 Nov 2005 No. 1515 1173-8324/10/1515-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of MK
Inpharma 1515 - 26 Nov 2005
■ An experimental integrase inhibitor, MK 0518,*effectively reduces viral RNA in previously untreatedpatients with HIV infection, according to initialfindings from a study presented at the European AIDSClinical Society meeting. In this multicentre, phase IItrial, 35 antiretroviral-naive patients with HIV infectionwere randomised to receive MK 0518 at a dose of100mg, 200mg, 400mg or 600mg, or placebo, twicedaily for 10 days. HIV RNA reductions of 1.7 to2.2 log10 copies/mL were observed across theMK 0518 groups, compared with a reduction of only0.2 log10 copies/mL for the placebo recipients(p < 0.001). More than 50% of each MK 0518 groupachieved HIV RNA levels of < 400 copies/mL byday 10. The treatment was also well tolerated with nodiscontinuations due to adverse effects or seriousadverse effects reported.* Merck & Co; phase II for HIV-1 infection in Ireland
Merck and Co Inc. Results of an Initial Phase II Study Showed ThatMK-0518, an Investigational Integrase Inhibitor, Provided Superior Reductionin HIV Viral RNA vs. Placebo in Treatment-Naive HIV-infected Patients.Media Release : 18 Nov 2005. Available from: URL: http://www.merck.com 809057198
1
Inpharma 26 Nov 2005 No. 15151173-8324/10/1515-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
